Document Detail

Telaprevir user's guide.
MedLine Citation:
PMID:  22212567     Owner:  NLM     Status:  In-Data-Review    
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a regimen of telaprevir combined with pegylated interferon alfa and ribavirin (PR) over PR alone in patients with HCV genotype 1. In the ADVANCE trial in treatment-naïve patients, 12 weeks of telaprevir, peginterferon alfa-2a and ribavirin followed by either 12 or 36 weeks of PR alone (depending upon extended rapid virologic response, or eRVR, i.e. HCV RNA undetectability at weeks 4 and 12), was associated with sustained virological response (SVR) in 75% of patients compared with 46% receiving PR for 48 weeks. The ILLUMINATE trial established the foundation for response-guided therapy in patients with eRVR. The REALIZE trial in treatment-experienced patients showed a gradient of SVR from prior relapsers (86%) to partial responders (57%) to null responders (31%), with rates of virologic failure and emergent resistance highest in the latter group. Incremental adverse effects of telaprevir include rash, anemia, pruritus, diarrhea, and nausea. Treatment naïve patients and relapsers are eligible for response-guided therapy. Stopping rules of telaprevir-based treatment include HCV RNA > 1000 IU/ml at weeks 4 and 12.
Ann Marie Liapakis; Ira Jacobson
Related Documents :
21952097 - Temporal trends of disability progression in multiple sclerosis: findings from british ...
22035147 - Evaluation of effectiveness of stellate ganglion block (sgb) treatment of sudden hearin...
10763937 - Is helicobacter pylori eradication associated with gastroesophageal reflux disease?
10579057 - Predictors of failure of helicobacter pylori eradication and predictors of ulcer recurr...
21885487 - Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituxima...
11589487 - Persistent fungemia--risk factors and outcome in 40 episodes.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  32 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-25     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New targets for antiviral therapy of chronic hepatitis C.
Next Document:  Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.